Welcome to our dedicated page for ProPhase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.
ProPhase Labs, Inc. (PRPH) is a diversified natural health medical science company that specializes in providing a wide range of diagnostic and consumer products. The company's operations are divided into two primary segments: Diagnostic Services and Consumer Products.
The Diagnostic Services segment offers COVID-19 diagnostic testing to a broad range of customers across the United States, including health plans, third-party payers, and government organizations. This segment is focused on delivering timely and accurate diagnostic information, critical during the ongoing pandemic and beyond.
The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) healthcare products and dietary supplements within the United States. In addition to these offerings, ProPhase Labs also provides personal genomics products and services, enabling consumers to gain insights into their genetic makeup.
ProPhase Labs is committed to advancing health and wellness through innovative products and services. Recent achievements include the development of the BE-Smart Esophageal Cancer Test, leveraging the company's AI platform and extensive genomics database. This test represents a significant step forward in cancer diagnostics and showcases the company's commitment to leveraging advanced technologies for improved healthcare outcomes.
Moreover, ProPhase Labs has projects such as Project ZenQ-AI and Equivir, which underline the company's focus on continuous research and innovation. These initiatives highlight ProPhase Labs' role in pushing the boundaries of medical science and consumer health products.
Financially, ProPhase Labs maintains a solid position, with ongoing projects and partnerships further strengthening its market presence. The company actively communicates with its retail investors through multiple channels, ensuring transparency and engagement with its stakeholders.
For more information, visit ProPhase Labs.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced its presentation at the Planet MicroCap Showcase: VIRTUAL 2022 on December 7, 2022, at 2:30 PM EST, hosted by CEO Ted Karkus. The event will be accessible via a live webcast. ProPhase is a diversified diagnostics, genomics, and biotech company, leveraging CLIA lab services for whole genome sequencing and traditional molecular testing, including COVID-19. The company aims to expand its clinical and genomics testing capabilities, while also focusing on developing new drugs and collaborations in the medical field.
ProPhase Labs (NASDAQ: PRPH) reported strong Q3 2022 results, achieving a record net revenue of $24.2 million, marking a 155% increase year-over-year. The company also noted a net income of $1.0 million, a turnaround from a $4.0 million loss in Q3 2021. Adjusted EBITDA stood at $6.3 million, a significant improvement from a loss of $1.3 million in the previous year. Cash and equivalents totaled $26.5 million. The company is expanding its services, collaborating with G42 Healthcare, and developing a cancer treatment with Dana-Farber Cancer Institute.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced a two-year collaboration with Dana-Farber Cancer Institute to develop Linebacker-1 (LB-1), a small molecule aimed at enhancing chemotherapy. This partnership will explore LB-1's tumoricidal effects when co-administered with traditional chemotherapy agents in vitro and in vivo. The project has a budget of $2-5 million over 18 months, targeting preclinical studies and a Phase 1 human clinical trial. ProPhase expects LB-1 to have multi-billion-dollar potential in oncology.
ProPhase Labs (NASDAQ: PRPH) announced its participation in the Q4 Investor Summit Conference on November 14, 2022, at the Sheraton New York Times Square Hotel. CEO Ted Karkus will present at 3:00 PM ET. The conference is complimentary for qualified investors, with 1x1 meetings available. The company focuses on diagnostics, genomics, and biotech solutions, leveraging its CLIA lab services for whole genome sequencing and providing COVID-19 testing among others.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on November 10, 2022, at 11:00 a.m. Eastern time to discuss its third quarter results for the period ended September 30, 2022. A press release with detailed results will be issued prior to the call. The call will be hosted by CEO Ted Karkus and feature a Q&A session. Participants can register online or use dial-in numbers for access. The call will also be broadcast live and accessible for replay.
ProPhase Labs, Inc. (NASDAQ: PRPH) has announced a collaboration with G42 Healthcare to enhance genomic sequencing capabilities. This partnership aims to create an advanced genomic sequencing facility in the U.S. and explore opportunities in genomic data sharing and artificial intelligence. The initiative focuses on the development of personalized medical treatments, targeting high-growth markets globally. ProPhase plans to expand its New York headquarters and intends to leverage its CLIA lab services for whole genome sequencing and diagnostics, aiming for operational efficiencies and cost savings.
ProPhase Labs, Inc. (NASDAQ: PRPH) will participate in The ThinkEquity Conference on October 26, 2022, at the Mandarin Oriental Hotel in New York. CEO Ted Karkus is scheduled to present at 11:30 AM ET. The event will include opportunities for one-on-one investor meetings and will also be live-streamed. ProPhase Labs focuses on diagnostics, genomics, and biotech, leveraging CLIA lab services for whole genome sequencing and COVID-19 testing. Visit www.ProPhaseLabs.com for more information.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced the addition of Dr. Russ B. Altman to the Advisory Board of its subsidiary, Nebula Genomics. Dr. Altman is a distinguished professor at Stanford University with expertise in bioengineering and genomics. His appointment is expected to enhance Nebula's strategic direction and product development in direct-to-consumer whole genome sequencing. ProPhase also plans to significantly expand its Garden City headquarters, building a new genomics lab equipped for advanced sequencing and genetic testing.
ProPhase Labs, a diversified diagnostics and biotech company, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 2:30 PM ET. CEO Ted Karkus will overview the company's offerings, including genomic services and COVID-19 testing. The hybrid conference runs from September 12-14, 2022, at the Lotte New York Palace Hotel. Interested institutional investors can register here.
ProPhase Labs (NASDAQ: PRPH) reported record Q2 2022 net revenues of $29.1 million, a 218% increase year-over-year, alongside a net income of $7.4 million, up 633% from the previous year. Adjusted EBITDA reached $12.4 million. The company performed 188,000 diagnostic tests in the quarter, significantly up from 56,000 in Q2 2021. Cash and equivalents totaled $27.5 million, with working capital at $53.5 million. Future expansions include a new subsidiary for drug development and a $6 million stock repurchase program.
FAQ
What is the current stock price of ProPhase Labs (PRPH)?
What is the market cap of ProPhase Labs (PRPH)?
What does ProPhase Labs, Inc. do?
What are the main segments of ProPhase Labs' operations?
What services does the Diagnostic Services segment provide?
What products are offered in the Consumer Products segment?
What is the BE-Smart Esophageal Cancer Test?
What recent projects has ProPhase Labs undertaken?
How does ProPhase Labs engage with its investors?
How does ProPhase Labs contribute to healthcare?
